Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan
- 1 April 2004
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 93 (7) , 943-946
- https://doi.org/10.1016/j.amjcard.2003.12.031
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial HypertensionChest, 2003
- Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertensionClinical Pharmacology & Therapeutics, 2003
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJournal of the American College of Cardiology, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Big Endothelin-1 and Endothelin-1 Plasma Levels Are Correlated With the Severity of Primary Pulmonary HypertensionChest, 2001
- Vasodilator Therapy for Primary Pulmonary Hypertension in ChildrenCirculation, 1999
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1993
- Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)Annals of Internal Medicine, 1990